A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the Proliferation, Immune response and RNA splicing modules in breast cancer

IntroductionSeveral gene expression signatures have been proposed and demonstrated to be predictive of outcome in breast cancer. In the present article we address the following issues: Do these signatures perform similarly? Are there (common) molecular processes reported by these signatures? Can better prognostic predictors be constructed based on these identified molecular processes?MethodsWe performed a comprehensive analysis of the performance of nine gene expression signatures on seven different breast cancer datasets. To better characterize the functional processes associated with these signatures, we enlarged each signature by including all probes with a significant correlation to at least one of the genes in the original signature. The enrichment of functional groups was assessed using four ontology databases.ResultsThe classification performance of the nine gene expression signatures is very similar in terms of assigning a sample to either a poor outcome group or a good outcome group. Nevertheless the concordance in classification at the sample level is low, with only 50% of the breast cancer samples classified in the same outcome group by all classifiers. The predictive accuracy decreases with the number of poor outcome assignments given to a sample. The best classification performance was obtained for the group of patients with only good outcome assignments. Enrichment analysis of the enlarged signatures revealed 11 functional modules with prognostic ability. The combination of the RNA-splicing and immune modules resulted in a classifier with high prognostic performance on an independent validation set.ConclusionsThe study revealed that the nine signatures perform similarly but exhibit a large degree of discordance in prognostic group assignment. Functional analyses indicate that proliferation is a common cellular process, but that other functional categories are also enriched and show independent prognostic ability. We provide new evidence of the potentially promising prognostic impact of immunity and RNA-splicing processes in breast cancer.

[1]  J. Bergh,et al.  Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[3]  J. Bergh,et al.  Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series , 2007, Clinical Cancer Research.

[4]  S. Drăghici,et al.  Transforming function of the LSM1 oncogene in human breast cancers with the 8p11–12 amplicon , 2007, Oncogene.

[5]  R. Gelber,et al.  Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  R W Blamey,et al.  Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999. , 2007, European journal of cancer.

[7]  G M Lenoir,et al.  A BRCA1 nonsense mutation causes exon skipping. , 1998, American journal of human genetics.

[8]  Andy J. Minn,et al.  Genes that mediate breast cancer metastasis to lung , 2005, Nature.

[9]  G. Fuller,et al.  A mutation-created novel intra-exonic pre-mRNA splice site causes constitutive activation of KIT in human gastrointestinal stromal tumors , 2005, Oncogene.

[10]  L. Miller,et al.  Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas. , 2007, Cancer research.

[11]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[12]  J. Venables.  Unbalanced alternative splicing and its significance in cancer , 2006, BioEssays : news and reviews in molecular, cellular and developmental biology.

[13]  Z. Szallasi,et al.  A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers , 2006, Nature Genetics.

[14]  Judith Abrams,et al.  Multiple interacting oncogenes on the 8p11-p12 amplicon in human breast cancer. , 2006, Cancer research.

[15]  C. Sotiriou,et al.  Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? , 2007, Nature Reviews Cancer.

[16]  P. Hall,et al.  An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  C. Perou,et al.  Molecular portraits and the family tree of cancer , 2002, Nature Genetics.

[18]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[19]  S. Paik.  Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. , 2007, The oncologist.

[20]  Robert J. Mayer,et al.  National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. , 2001, Journal of the National Cancer Institute.

[21]  Luigi Mariani,et al.  Estimation of predictive accuracy in survival analysis using R and S-PLUS , 2007, Comput. Methods Programs Biomed..

[22]  Ajay N. Jain,et al.  Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. , 2006, Cancer cell.

[23]  L. V. van't Veer,et al.  Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. , 2006, Journal of the National Cancer Institute.

[24]  M. Pajares,et al.  Alternative splicing: an emerging topic in molecular and clinical oncology. , 2007, The Lancet. Oncology.

[25]  Gavin D. Grant,et al.  Common markers of proliferation , 2006, Nature Reviews Cancer.

[26]  A. Nobel,et al.  Concordance among Gene-Expression – Based Predictors for Breast Cancer , 2011 .

[27]  Yudong D. He,et al.  A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .

[28]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[29]  Fabien Reyal,et al.  Pooling breast cancer datasets has a synergetic effect on classification performance and improves signature stability , 2008, BMC Genomics.

[30]  Howard Y. Chang,et al.  Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[31]  A. Nobel,et al.  The molecular portraits of breast tumors are conserved across microarray platforms , 2006, BMC Genomics.

[32]  L. Ein-Dor,et al.  Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[34]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[35]  J. Venables.  Aberrant and Alternative Splicing in Cancer , 2004, Cancer Research.

[36]  Stefan Michiels,et al.  Gene expression profiling: does it add predictive accuracy to clinical characteristics in cancer prognosis? , 2007, European journal of cancer.

[37]  Laurence J Miller,et al.  Targeting the RNA splicing machinery as a novel treatment strategy for pancreatic carcinoma. , 2006, Cancer research.

[38]  Yi Zhang,et al.  Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer , 2007, BMC Cancer.

[39]  M. J. van de Vijver,et al.  Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. , 2006, Journal of the National Cancer Institute.

[40]  Robert Gray,et al.  Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  L. Coussens,et al.  The inflammatory tumor microenvironment and its impact on cancer development. , 2006, Contributions to microbiology.

[42]  I. Ellis,et al.  An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer , 2007, Genome Biology.

[43]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[44]  I. Ellis,et al.  A consensus prognostic gene expression classifier for ER positive breast cancer , 2006, Genome Biology.

[45]  G. Sherlock,et al.  The prognostic role of a gene signature from tumorigenic breast-cancer cells. , 2007, The New England journal of medicine.

[46]  Marc Buyse,et al.  Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial , 2006, Nature Clinical Practice Oncology.

[47]  L. Holmberg,et al.  Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts , 2005, Breast Cancer Research.

[48]  Catherine Legrand.  1687Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials : Early Breast Cancer Trialists' Collaborative Group (EBCTCG) , 2005 .

[49]  M. Schemper,et al.  Predictive Accuracy and Explained Variation in Cox Regression , 2000, Biometrics.

[50]  P. Ravdin,et al.  Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  A. Glas,et al.  The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study , 2009, Breast Cancer Research and Treatment.